SMFStreet's Blog Posts Tagged 'Seattle' (1)

SGEN Seattle Genetics: ThinkEquity believes SGN-35 at ASH-10 outperforms expectation



ThinkEquity notes that, based on strength of full ASH-10 SGN-35 Relapsed Refractory (RR) Hodgkin's Lymphoma (HL) data and KOL "buzz", they believe a surprise full FDA label is possible. They believe broad approval across HL and ALCL (including front-line) would decrease reimbursement risk and achievement of their peak sales ests. They maintain their Buy rating and $19 tgt based on SGN-35 data, their…